Bruce German, PhD

Bruce is a Professor of Food Chemistry at UC Davis and the Director of the Foods for Health Institute located in the Robert Mondavi Institute. Bruce has had a long and highly distinguished career in understanding the role of food and certain food ingredients in delivering improved health. His particular expertise is in the nutrient delivery between mothers and infants in the first few months of life. Throughout his career, Bruce has served as an expert advisor to the world's leading food and nutrition companies and organizations.


Daniel Janney, MBA

Dan is the Managing Director of Alta Partners, a leading venture capital firm in life sciences, funding over 145 companies in the industry since 1996. Dan joined Alta immediately following the firm’s founding, and was co-founder of the Alta BioPharma effort. Dan focuses on investments in biopharmaceutical products and therapeutics and has been directly involved in the funding and development of over 25 life sciences companies. Dan is currently on the Board of Directors of a number of companies, including Alba Therapeutics, Esperion Therapeutics, Lithera, Prolacta Bioscience, and ViroBay. In addition, he led Alta’s investments in ChemGenex Pharmaceuticals, CoTherix, Definity Health, DiscoveRx, Dynavax, Endonetics, Ilex Oncology, InterMune, LJL Biosystems and Mako Surgical.


Catherine J. Mackey, PhD

Catherine J. Mackey, Ph.D., is an experienced corporate director and advisor with over thirty years of accomplishment in the biotechnology, pharmaceutical, and agricultural industries. She is CEO of CYPrus Therapeutics, Inc. and Chairman of the Board of Cour Pharma, Inc. In addition, she serves on the Boards of Directors of Sequenom (SQNM), Viventia Bio Inc., and Rady Children’s Hospital, and is an Advisor to several companies, including Cypher Genomics and FHOOSH. Dr. Mackey received her B.S. and Ph.D. degrees in microbiology and genetics from Cornell University. She is the former Vice President of DEKALB Genetics, Inc, and Sr. Vice President of Pfizer Global Research and Development.

David Kyle, PhD

David is a 30 year veteran of biotech, having co-founded a range of successful biotech companies in the fields of nutrition and health (including Martek Biosciences, which was acquired in 2011 for $1.1 Billion). David combines a strong scientific background with significant commercial acumen, has published over 70 scientific articles, edited two books, and is the named inventor on over 80 patents.


Simon Barnes, PhD, MBA

Simon Barnes is a Partner of Circadia Ventures and manages a venture capital fund backed by the global ingredient company Tate & Lyle. Simon has spent 15 years in and around the life sciences venture capital industry, first with the London office of Atlas Venture and subsequently with GIMV Venture Capital. He has served on a number of VC-backed boards from early stage to exit including Allylix (USA), Fugeia (Belgium) and Lumora (UK). Simon has a first class honors degree in Natural Sciences and a PhD from The University of Cambridge, UK. He spent two years as a Research Fellow at The Rockefeller University in New York, before becoming Head of The Laboratory of Cotton Biotechnology in Singapore. He holds an MBA with Distinction from Imperial College London, later joining the faculty and becoming Director of Imperial's Entrepreneurship Centre prior to co-founding Circadia Ventures in 2006.

Anne Lo, BSc, BVM&S, PhD

Dr. Anne Lo represents Horizons Ventures on the Evolve Biosystems board of directors. She trained as a veterinary surgeon and worked in a number of clinical roles, including the Equestrian Events at the Beijing Olympics before taking up a position as Junior Fellow at the Cambridge Infectious Diseases Consortium, specializing in Influenza A virus. She subsequently joined strategy consulting firm Bain & Co' s London office, working on a wide range of private equity and corporate projects, and then moved to execute strategic 5 year plan initiatives for Worldpay, a Bain Capital and Advent International portfolio company. She primarily covers biotechnology, life sciences and healthcare investments at Horizons.

Dr. Lo received her BSc and BVM&S degrees from the University of Edinburgh and PhD from the University of Cambridge in the United Kingdom.